Flagyl safe for pregnancy

https://pocketpcmedicine.com/top/celebrity-parents-who-have-twins/

The Paul-Ehrlich-Institut has approved the first clinical trial for a vaccine against Covid-19 in Germany. Thus, the Mainz biotechnology company BioNTech has developed a vaccine candidate can be tested in humans. First, tolerability and safety are in the foreground.

The whole world is waiting for an effective vaccine against Covid-19. Clinical studies, in which vaccine candidates are the people tested, are important milestones on the way there. In Germany can now start, following approval by the Paul-Ehrlich-Institute, the world’s fifth trial for a vaccine to be used with proven safety and effectiveness as quickly as possible around the world.

Topics Of Special Coronavirus

More recent contributions to SARS-CoV-2, and Covid-19 can be found in the special Coronavirus on aponet.de.

Vaccine enthält the genome of SARS-CoV-2

Initially, the tolerability of the vaccine candidates and the generation of a specific stand immune response in the foreground. In the first stage, 200 healthy adults up to 55 years of age are vaccinated with different doses of the vaccine. If first results are available, should be included in a second step, people with an increased risk of infection or risk for a severe course of the disease.

In the case of the company’s vaccine candidate is a RNA vaccine, which contains the genetic material for a part of the Corona Virus called SARS-CoV-2. Injected into the muscle, absorbed the genetic material of the cells of the body, produce a viral protein. Since it is not complete of viruses, there is no danger of infection. If everything works as planned, to detect immune cells, these cells of the body infected, and ensure that a protective response at the end of immune.

ZOU

An Overview of all the messages you get on aponet.de current.